Download PDF
Semin Vasc Med 2002; 02(4): 383-390
DOI: 10.1055/s-2002-36767
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diabetes and Impaired Glucose Tolerance: A Review of the Epidemiological and Trial Evidence for Their Role in Cardiovascular Risk

Louise Bowman, Jane Armitage
  • 1Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Medicine, Radcliffe Infirmary, Oxford, United Kingdom
Further Information

Publication History

Publication Date:
22 January 2003 (online)

    Permissions and Reprints

ABSTRACT

People with diabetes mellitus are at increased risk of cardiovascular disease (CVD). There is a higher prevalence of recognized risk factors, such as hypertension and abnormal blood lipids, in the diabetic population and this may account for some of the increase in risk. However, the epidemiological evidence suggests that hyperglycemia per se is itself a risk factor for CVD, with no evidence of a lower threshold below which risk does not continue to fall. In the past, the cut-offs for considering an individual to have diabetes or not have been determined according to the risk of microvascular complications. If the relationship between glycemia and macrovascular complications is continuous throughout the range it may be arbitrary what level is used for diagnosis. Trials of lipid-lowering, and blood pressure reduction in diabetes have shown significant benefits for CVD prevention. This applies both to the reduction of elevated levels of blood pressure and cholesterol and, more recently, to lowering of these risk factors within the "normal" range. Randomized evidence for glucose lowering is not as conclusive, but it seems likely that glucose control should be treated in a similar manner.

KEYWORD

Diabetes mellitus - impaired glucose tolerance - risk factor - cardiovascular disease - hyperglycemia

REFERENCES

  • 1 Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus.  Diabetologia . 1987;  30 123-131
    CrossrefPubMedGoogle Scholar
  • 2 Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view.  Diabetes Metab Rev . 1987;  3 463-524
    PubMedGoogle Scholar
  • 3 Królewski A S, Czyzyk A, Janeczko D, Kopczýnski J. Mortality from cardiovascular disease.  Diabetologia . 1977;  13 345-350
    CrossrefPubMedGoogle Scholar
  • 4 Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes.  Diabetes Care . 1995;  18 258-268
    PubMedGoogle Scholar
  • 5 Garcia M J, McNamara P M, Gordon T, Kanal W B. Morbidity and mortality in diabetes in the Framingham population.  Diabetes . 1974;  23 105-111
    CrossrefPubMedGoogle Scholar
  • 6 Stamler J, Vaccaro O, Neaton J D, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial.  Diabetes Care . 1993;  16 434-444
    CrossrefPubMedGoogle Scholar
  • 7 West K M, Ahuja M MS, Bennett P H. The role of circulating glucose and triglyceride concentrations and their interactions with other "risk factors" as determinants of arterial disease in nine diabetic population samples from WHO Multinational Study.  Diabetes Care . 1983;  6 361-369
    CrossrefPubMedGoogle Scholar
  • 8 Head J, Fuller J H. International variations in mortality among diabetic patients: the WHO multinational study of vascular disease in diabetes.  Diabetologia . 1990;  33 477-481
    CrossrefPubMedGoogle Scholar
  • 9 Kawate R, Miyanishi M, Yamakido M, Nishimoto Y. Preliminary studies of the prevalence and mortality of diabetes mellitus in Japanese in Japan and on the island of Hawaii.  Advances in Metabolic Disorders . 1978;  9 201-224
    PubMedGoogle Scholar
  • 10 Kannell W B, McGee D L. Diabetes and cardiovascular risk factors: the Framingham Study.  Circulation . 1979;  59 8-13
    PubMedGoogle Scholar
  • 11 Barrett-Connor E L, Cohn B A, Wingard D L, Edelstein S L. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men?.  The Rancho Bernardo Study. JAMA . 1991;  265 627-631
    CrossrefPubMedGoogle Scholar
  • 12 Laing S P, Swerdlow A J, Slater S D. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus.  Diabet Med . 1999;  16 466-471
    CrossrefPubMedGoogle Scholar
  • 13 Winocour P H, Durrington P N, Ishola M, Hillier V F, Anderson D C. The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus.  Q J Med . 1989;  70 265-276
    PubMedGoogle Scholar
  • 14 Betteridge D J. Lipids, diabetes, and vascular disease: the time to act.  Diabet Med . 1989;  6 195-218
    PubMedGoogle Scholar
  • 15 Manley S E, Frighi V, Stratton I M. UK Prospective Diabetes Study 27: plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex.  Diabetes Care . 1997;  20 1683-1687
    PubMedGoogle Scholar
  • 16 Austin M A, Breslow J L, Hennekens C H. Low-density lipoprotein subclass patterns and risk of myocardial infarction.  JAMA . 1988;  260 1917-1921
    CrossrefPubMedGoogle Scholar
  • 17 Lamarche B, Tchernof A, Moorjani S. Small, dense low-density lipoprotein particles as a predictor of the risk of ischaemic heart disease in men. Prospective results from the Quebec Cardiovascular Study.  Circulation . 1997;  95 69-75
    PubMedGoogle Scholar
  • 18 Stamler J, Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded?.  <~>Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA . 1986;  256 2823-2828
    CrossrefPubMedGoogle Scholar
  • 19 MacMahon S, Peto R, Cutler J. Blood pressure, stroke and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.  Lancet . 1990;  335 765-774
    CrossrefPubMedGoogle Scholar
  • 20 Turner R, Holman R, Stratton I. Tight blood pressure control and risk of macrosvascular and microvascular complications in type 2 diabetes: UKPDS 38.  Br Med J . 1998;  317 703-726
    PubMedGoogle Scholar
  • 21 PROGRESS Collaborative Group. Randomised trial of perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.  Lancet . 2001;  358 1033-1041
    CrossrefPubMedGoogle Scholar
  • 22 The Long-Term Intevention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.  N Engl J Med . 1998;  339 1349-1357
    CrossrefPubMedGoogle Scholar
  • 23 Heart Protection Study Collaborative Group. MRC-BHF Heat Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals; randomised placebo-controlled trial.  Lancet . 2002;  360 7-22
    CrossrefPubMedGoogle Scholar
  • 24 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med . 2000;  342 145-153
    CrossrefPubMedGoogle Scholar
  • 25 Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus.  Ann Intern Med . 1996;  124 127-130
    PubMedGoogle Scholar
  • 26 Uusitupa M, Siitonen O, Aro A, Pyörälä K. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects.  Diabetologia . 1985;  28 22-27
    CrossrefPubMedGoogle Scholar
  • 27 UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors.  Diabetes Res . 1990;  13 1-11
    PubMedGoogle Scholar
  • 28 Haffner S M, Stern M P, Hazuda H P, Mitchell B D, Patterson J K. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?.  JAMA . 1990;  263 2893-2898
    CrossrefPubMedGoogle Scholar
  • 29 Haffner S M, Mykkänen L, Festa A, Burke J P, Stern M P. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Implications for preventing coronary heart disease during the prediabetic state.  Circulation . 2000;  101 975-980
    PubMedGoogle Scholar
  • 30 McPhillips J B, Connor E B, Wingard D L. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults.  Am J Epidemiol . 1990;  131 443-453
    PubMedGoogle Scholar
  • 31 Ruige J B, Assendelft W JJ, Dekker J M. Insulin and risk of cardiovascular disease.  A meta-analysis. Circulation . 1998;  97 996-1001
    PubMedGoogle Scholar
  • 32 Groeneveld Y, Petri H, Hermans J, Springer M P. Relationship between blood glucose level and mortality in Type 2 diabetes mellitus: a systematic review.  Diabet Med . 1999;  16 2-13
    CrossrefPubMedGoogle Scholar
  • 33 Stratton I M, Adler A I, Neil A W, on behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ . 2000;  321 405-412
    CrossrefPubMedGoogle Scholar
  • 34 University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. I. Design, methods and baseline results.  Diabetes . 1970;  19(suppl) 747-783
    PubMedGoogle Scholar
  • 35 The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial.  Am J Cardiol . 1995;  75 894-903
    CrossrefPubMedGoogle Scholar
  • 36 UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance.  Diabetologia . 1991;  34 877-890
    CrossrefPubMedGoogle Scholar
  • 37 ADVANCE Management Committee. Study rationale and design of ADVANCE: Action in diabetes and MR controlled evaluation.  Diabetologia . 2001;  44 1118-1120
    CrossrefPubMedGoogle Scholar
  • 38 US Department of Veterans Affairs Cooperative Studies Program. Glycemic Control and Complications in Diabetes Mellitus Type 2 - CSP#465. Current Controlled Clinical Trials Register. www.controlled-trials.com
  • 39 National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.  Diabetes . 1979;  28 1039-1057
    PubMedGoogle Scholar
  • 40 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care . 1997;  20 1183-1197
    PubMedGoogle Scholar
  • 41 Harris M I. Impaired glucose tolerance-prevalence and conversion to NIDDM.  Diabet Med . 1996;  13 S9-S11
    CrossrefPubMedGoogle Scholar
  • 42 Stamler R, Stamler J, Schoenberger J A. Relationship of glucose tolerance to prevalence of ECG abnormalities and to 5-year mortality from cardiovascular disease. Findings of the Chicago Heart Association Detection Project in Industry.  J Chron Dis . 1979;  32 817-837
    CrossrefPubMedGoogle Scholar
  • 43 Coutinho M, Wang Y, Gerstein H C, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.  Diabetes Care . 1999;  22 233-240
    CrossrefPubMedGoogle Scholar
  • 44 Balkau B, Shipley M, Jarrett R J. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men.  Diabetes Care . 1998;  21 360-367
    PubMedGoogle Scholar
  • 45 Qureshi A I, Giles W H, Croft J B. Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction. The Third National Health and Nutrition Examination Survey.  Stroke . 1998;  29 1329-1332
    CrossrefPubMedGoogle Scholar
  • 46 Khaw K T, Wareham N, Luben R. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk).  BMJ . 2001;  322 15-18
    CrossrefPubMedGoogle Scholar
  • 47 Reaven G M. Banting Lecture, 1988. Role of insulin resistance in human disease.  Diabetes . 1988;  37 1596-1607
    PubMedGoogle Scholar
  • 48 Howard G H, O'Leary D H, Zaccaro D, for the IRAS Investigators. Insulin sensitivity and atherosclerosis.  Circulation . 1996;  93 1809-1817
    PubMedGoogle Scholar
      >